{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:46:42Z","timestamp":1785336402205,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Municipal and Commission Health and Family Planning","award":["2015-3-076"],"award-info":[{"award-number":["2015-3-076"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 81772154"],"award-info":[{"award-number":["Grant No. 81772154"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Major Infectious Diseases Such as AIDS and Viral Hepatitis Prevention and Control Technology Major Projects","award":["Grant No. 2018ZX10712-001"],"award-info":[{"award-number":["Grant No. 2018ZX10712-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      An increased number of refractory\n                      <jats:italic>mycoplasma pneumoniae<\/jats:italic>\n                      (MP) pneumonia (MPP) cases have been reported. However the duration of MP infection in lower airway and the course of anti-MP treatment remains unclear.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the medical records of 94 MPP children. Patients were classified into two groups. The long-term group (Group LT) was defined as bronchoalveolar lavage fluid (BALF) remained MP-positive by PCR after 30\u2009days of the disease course. The non-long-term group (Group NLT) was defined as BALF became MP-negative by PCR within 30\u2009days of disease and patients who only needed one bronchoscopy lavage therapy. MP loads, clinical outcomes were analyzed along with other clinical measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The average levels of inflammatory markers such as C reactive protein and lactate dehydrogenase in Group LT were significantly higher than those in Group NLT. Airway and lung damage in Group LT were more severe than Group NLT. 28 patients developed necrotizing pneumonia and 8 patients developed pulmonary embolism in Group LT. Mean maximum MP loads in BALF were 10\n                      <jats:sup>7.46\u2009\u00b1\u20090.93<\/jats:sup>\n                      and 10\n                      <jats:sup>4.86\u2009\u00b1\u20090.93<\/jats:sup>\n                      in Groups LT and NLT, respectively. There was persistent MP DNA in Group LT, even lasted for 120\u2009days. One severe MPP patient in Group LT had MP-associated bloodstream infection. After 3\u2009months of follow-up, chest imaging revealed incomplete absorption of pulmonary consolidation in 33 patients of Group LT [including 13 airway obliterans (AO) patients] and in 7 patients of Group NLT (including 2 AO patients).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MP loads of BALF were associated with the subsequent duration of MP DNA in lower airway. High MP loads and persistent long-term MP DNA in lower airway were associated with severity of pediatric MPP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-019-4667-y","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T09:05:04Z","timestamp":1575968704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["High Mycoplasma pneumoniae loads and persistent long-term Mycoplasma pneumoniae DNA in lower airway associated with severity of pediatric Mycoplasma pneumoniae pneumonia"],"prefix":"10.1186","volume":"19","author":[{"given":"Jinrong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"4667_CR1","first-page":"172","volume":"52","author":"L Chen","year":"2014","unstructured":"Chen L, Liu J, Zhao S, et al. Clinical features and treatment of refractory Mycoplasma pneumoniae pneumonia unresponded to conventional dose methylprednisolone in children. Zhonghua er ke za zhi = Chinese J Pediatr. 2014;52:172.","journal-title":"Zhonghua er ke za zhi = Chinese J Pediatr"},{"key":"4667_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jiac.2014.10.008","volume":"21","author":"N Miyashita","year":"2014","unstructured":"Miyashita N, Kawai Y, Inamura N, et al. Setting a standard for the initiation of steroid therapy in refractory or severe mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother. 2014;21:153\u201360.","journal-title":"J Infect Chemother"},{"key":"4667_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00508-007-0810-7","volume":"119","author":"F Daxboeck","year":"2007","unstructured":"Daxboeck F, Eisl B, Burghuber C, et al. Fatal mycoplasma pneumoniae pneumonia in a previously healthy 18-year-old girl. Wien Klin Wochenschr. 2007;119:379\u201384.","journal-title":"Wien Klin Wochenschr"},{"key":"4667_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<375::AID-PPUL10>3.0.CO;2-2","volume":"23","author":"MA Leong","year":"1997","unstructured":"Leong MA, Nachajon R, Ruchelli E, et al. Bronchitis obliterans due to mycoplasma pneumonia. Pediatr Pulmonol. 1997;23:375\u201381.","journal-title":"Pediatr Pulmonol"},{"key":"4667_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijid.2014.07.020","volume":"29","author":"M Wang","year":"2014","unstructured":"Wang M, Wang Y, Yan Y, et al. Clinical and laboratory profiles of refractory mycoplasma pneumoniae pneumonia in children. Int J Infect Dis. 2014;29:18\u201323.","journal-title":"Int J Infect Dis"},{"key":"4667_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fped.2018.00296","volume":"6","author":"JR Liu","year":"2018","unstructured":"Liu JR, Lu J, Dong F, et al. Low bacterial co-infection invalidates the early use of non-anti-mycoplasma pneumoniae antibiotics in pediatric refractory mycoplasma pneumoniae pneumonia patients. Front Pediatr. 2018;6:296.","journal-title":"Front Pediatr"},{"key":"4667_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12810","volume":"20","author":"OA Prince","year":"2018","unstructured":"Prince OA, Krunkosky TM, Sheppard ES, et al. Modelling persistent mycoplasma pneumoniae infection of human airway epithelium. Cell Microbiol. 2018;20:e12810.","journal-title":"Cell Microbiol"},{"key":"4667_CR8","first-page":"223","volume":"57","author":"A Tamura","year":"2008","unstructured":"Tamura A, Matsubara K, Tanaka T, et al. Methylprednisolone pulse therapy for refractory mycoplasma pneumoniae pneumonia in children. J Inf Secur. 2008;57:223\u20138.","journal-title":"J Inf Secur"},{"key":"4667_CR9","first-page":"77","volume":"25","author":"F Zhao","year":"2012","unstructured":"Zhao F, Cao B, He LH, et al. Evaluation of a new real-time PCR assay for detection of mycoplasma pneumoniae in clinical specimens. Biomed Environ Sci. 2012;25:77\u201381.","journal-title":"Biomed Environ Sci"},{"issue":"10","key":"4667_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141702","volume":"10","author":"F Zhao","year":"2015","unstructured":"Zhao F, Liu L, Tao X, He L, Meng F, Zhang J. Culture-independent detection and genotyping of mycoplasma pneumoniae in clinical specimens from Beijing. China PloS one. 2015;10(10):e0141702.","journal-title":"China PloS one"},{"key":"4667_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1099\/00222615-48-12-1115","volume":"48","author":"JW Dorigo-Zetsma","year":"1999","unstructured":"Dorigo-Zetsma JW, Zaat SA, Vriesema AJ, et al. Demonstration by a nested PCR for Mycoplasma pneumoniae that M pneumoniae load in the throat is higher in patients hospitalised for M pneumoniae infection than in non-hospitalised subjects. J Med Microbiol. 1999;48:1115.","journal-title":"J Med Microbiol"},{"key":"4667_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2334-10-39","volume":"10","author":"AC Nilsson","year":"2010","unstructured":"Nilsson AC, Bjorkman P, Welinder-Olsson C, et al. Clinical severity of mycoplasma pneumoniae (MP) infection is associated with bacterial load in oropharyngeal secretions but not with MP genotype. BMC Infect Dis. 2010;10:39.","journal-title":"BMC Infect Dis"},{"key":"4667_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1471-2180-8-93","volume":"8","author":"AC Nilsson","year":"2008","unstructured":"Nilsson AC, Bj\u00f6rkman P, Persson K, et al. Polymerase chain reaction is superior to serology for the diagnosis of acute mycoplasma pneumoniae infection and reveals a high rate of persistent infection. BMC Microbiol. 2008;8:93.","journal-title":"BMC Microbiol"},{"key":"4667_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12666","volume":"19","author":"T Yamamoto","year":"2017","unstructured":"Yamamoto T, Kida Y, Sakamoto Y, et al. Mpn491, a secreted nuclease of mycoplasma pneumoniae, plays a critical role in evading killing by neutrophil extracellular traps. Cell Microbiol. 2017;19:e12666.","journal-title":"Cell Microbiol"},{"key":"4667_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/infdis\/jix559","volume":"217","author":"PM Meyer Sauteur","year":"2018","unstructured":"Meyer Sauteur PM, de Groot RCA, Estev\u00e3o SC, et al. The role of B cells in carriage and clearance of mycoplasma pneumoniae from the respiratory tract of mice. J Infect Dis. 2018;217:298\u2013309.","journal-title":"J Infect Dis"},{"key":"4667_CR16","doi-asserted-by":"crossref","unstructured":"Segovia JA CTWV. NLRP3 Is a Critical Regulator of Inflammation and Innate Immune Cell Response during Mycoplasma pneumoniae Infection. Infect Immun. 2017; 86. pii: e00548\u201317.","DOI":"10.1128\/IAI.00548-17"},{"key":"4667_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1128\/IAI.01249-06","volume":"75","author":"CM Salvatore","year":"2006","unstructured":"Salvatore CM, Fonseca-Aten M, Katz-Gaynor K, et al. Respiratory tract infection with mycoplasma pneumoniae in Interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation. Infect Immun. 2006;75:236\u201342.","journal-title":"Infect Immun"},{"key":"4667_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1128\/IAI.00878-07","volume":"76","author":"CM Salvatore","year":"2008","unstructured":"Salvatore CM, Fonseca-Aten M, Katz-Gaynor K, et al. Intranasal Interleukin-12 therapy inhibits mycoplasma pneumoniae clearance and sustains airway obstruction in murine pneumonia. Infect Immun. 2008;76:732\u20138.","journal-title":"Infect Immun"},{"key":"4667_CR19","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.micinf.2006.02.014","volume":"8","author":"HW Chu","year":"2006","unstructured":"Chu HW, Breed R, Rino JG, et al. Repeated respiratory mycoplasma pneumoniae infections in mice: effect of host genetic background. Microbes Infect. 2006;8:1764\u201372.","journal-title":"Microbes Infect"},{"key":"4667_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1165\/rcmb.2004-0197OC","volume":"32","author":"M Fonseca-Aten","year":"2005","unstructured":"Fonseca-Aten M, R\u00edos AM, Mej\u00edas A, et al. Mycoplasma pneumoniae induces host-dependent pulmonary inflammation and airway obstruction in mice. Am J Respir Cell Mol Biol. 2005;32:201\u201310.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"4667_CR21","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1128\/AAC.02060-12","volume":"57","author":"F Zhao","year":"2013","unstructured":"Zhao F, Liu G, Wu J, et al. Surveillance of macrolide-resistant mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013;57:1521\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"4667_CR22","doi-asserted-by":"publisher","first-page":"18.2","DOI":"10.1186\/s13756-019-0627-y","volume":"8","author":"F Zhao","year":"2019","unstructured":"Zhao F, Liu J, Shi W, et al. Antimicrobial susceptibility and genotyping of mycoplasma pneumoniae isolates in Beijing, China, from 2014 to 2016. Antimicrob Resist Infect Control. 2019;8:18.2.","journal-title":"Antimicrob Resist Infect Control"},{"key":"4667_CR23","volume":"13","author":"D Yang","year":"2018","unstructured":"Yang D, Chen L, Chen Z. The timing of azithromycin treatment is not associated with the clinical prognosis of childhood mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings. PLoS One. 2018;13:e191951.","journal-title":"PLoS One"},{"key":"4667_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12879-017-2500-z","volume":"17","author":"IA Yoon","year":"2017","unstructured":"Yoon IA, Hong KB, Lee HJ, et al. Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2017;17:402.","journal-title":"BMC Infect Dis"},{"key":"4667_CR25","doi-asserted-by":"publisher","unstructured":"Kutty PK, Jain S, Taylor TH, et al. Mycoplasma pneumoniae among children hospitalized with community-acquired pneumonia. Clin Infect Dis. 2018 May 17. https:\/\/doi.org\/10.1093\/cid\/ciy419 [Epub ahead of print].","DOI":"10.1093\/cid\/ciy419"},{"issue":"5","key":"4667_CR26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/jcm8050726","volume":"8","author":"Eun-Ae Yang","year":"2019","unstructured":"Yang EA, Kang HM, Rhim JW, et al. Early Corticosteroid Therapy for Mycoplasma pneumoniae Pneumonia Irrespective of Used Antibiotics in Children. J Clin Med. 2019; 8(5). doi: https:\/\/doi.org\/10.3390\/jcm8050726.","journal-title":"Journal of Clinical Medicine"},{"key":"4667_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4168\/aair.2014.6.1.22","volume":"6","author":"SY You","year":"2014","unstructured":"You SY, Jwa HJ, Yang EA, et al. Effects of Methylprednisolone Pulse Therapy on RefractoryMycoplasma pneumoniae Pneumonia in Children. Allergy, Asthma Immunol Res. 2014;6:22.","journal-title":"Allergy, Asthma Immunol Res"},{"key":"4667_CR28","doi-asserted-by":"publisher","first-page":"6724","DOI":"10.1073\/pnas.0510644103","volume":"103","author":"TR Kannan","year":"2006","unstructured":"Kannan TR, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci U S A. 2006;103:6724\u20139.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4667-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4667-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4667-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T19:59:30Z","timestamp":1607457570000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4667-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4667"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4667-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.10258\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.10258\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.10258\/v3","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"26 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Beijing Children\u2019s Hospital (No. 2017\u201323) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Participant consent was written by the guardian of all the patients and informed consent forms were archived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1045"}}